COMMUNIQUÉS West-GlobeNewswire

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
05/01/2026
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle East, is also planned [...]
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
05/01/2026
Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting [...]
BlossomHill Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12
05/01/2026
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, [...]
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
05/01/2026
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZ SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. ( [...]
Compass Therapeutics Announces Key Leadership Appointments
05/01/2026
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple [...]
HOOPP hits 500,000-member milestone, strengthening retirement security for Ontario’s healthcare community
05/01/2026
Half a million futures. One pension promise. TORONTO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan has surpassed the 500,000-membership mark, an important milestone that reflects HOOPP’s [...]
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
05/01/2026
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
05/01/2026
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
05/01/2026
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) [...]
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
05/01/2026
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ongoing – -- In [...]
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
05/01/2026
TARA-002 selected for FDA manufacturing development and readiness pilot program NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative [...]
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism
05/01/2026
REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a [...]
Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
05/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics , a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today [...]
Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer
05/01/2026
Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD [...]
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
05/01/2026
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare Conference on January 12, [...]
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
05/01/2026
BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) (“OraSure” and “OTI”), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced [...]
Stryker to announce financial results for its fourth quarter and full year 2025
05/01/2026
Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be [...]
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
05/01/2026
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst [...]
SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson’s Disease
05/01/2026
SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. [...]

Pages